Substance-induced or substance-associated primary psychoses? Continuing the discussion. A response to I.А. Fedotov, et al
- Authors: Cherro M.1, Jatchavala C.2, Handuleh D.3, Ransing R.4, Shoib S.5, Őri D.6, Ojeahere M.I.7, Soler-Vidal J.8, Pereira-Sanchez V.9
-
Affiliations:
- American University of Beirut
- Prince of Songkla University
- Saint Paul's Hospital Millennium Medical College
- BKL Walawalkar Rural Medical College
- Jawahar Lal Nehru Memorial Hospital
- Heim Pál National Pediatric Institute
- Jos University Teaching Hospital
- FIDMAG Research Foundation
- NYU Grossman School of Medicine
- Issue: Vol 29, No 1 (2021)
- Pages: 171-176
- Section: Letter in edition
- URL: https://journals.rcsi.science/pavlovj/article/view/65222
- DOI: https://doi.org/10.23888/PAVLOVJ2021291171-176
- ID: 65222
Cite item
Abstract
This letter to the editor continues the discussion about the similarities and differences between secondary psychosis and schizophrenia, which was initiated by the authors of the article «Substance-induced psychosis and schizophrenia: the interaction point» (Fedotov I.A., Quattrone D., Shustov D.I. Substance-induced psychosis and schizophrenia: the interaction point. I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):593-604. doi:10.238 88/PAVLOVJ2020284593-604).
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Michelle Cherro
American University of Beirut
Author for correspondence.
Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-4526-2595
MD, Post-Graduate Resident, Department of Psychiatry, Faculty of Medicine
Lebanon, Beirut, LebanonChonnakarn Jatchavala
Prince of Songkla University
Email: mc119@aub.edu.lb
ORCID iD: 0000-0001-9765-2184
MD, M.Sc., Department of Psychiatry, Faculty of Medicine
Thailand, Songkla, Hat Yai, ThailandDJibril I.M. Handuleh
Saint Paul's Hospital Millennium Medical College
Email: mc119@aub.edu.lb
ORCID iD: 0000-0003-2662-1078
MD, Resident, Department of Psychiatry
Ethiopia, Addis Ababa, EthiopiaRamdas Ransing
BKL Walawalkar Rural Medical College
Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-5040-5570
MD, Assistant Professor, Department of Psychiatry
India, Maharashtra, IndiaSheikh Shoib
Jawahar Lal Nehru Memorial Hospital
Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-3739-706X
MD, Psychiatrist, Department of Psychiatry
India, Rainawari, Kashmir, IndiaDorottya Őri
Heim Pál National Pediatric Institute
Email: mc119@aub.edu.lb
ORCID iD: 0000-0003-0878-165X
MD, Child and adolescent psychiatrist, Department of Mental Health
Hungary, Budapest, HungaryMargaret Isioma Ojeahere
Jos University Teaching Hospital
Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-0593-2400
MD, Psychiatrists, Department of Psychiatry
Nigeria, Jos, Plateau State, NigeriaJoan Soler-Vidal
FIDMAG Research Foundation
Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-9809-8477
MD, Researcher
Spain, Barcelona, SpainVictor Pereira-Sanchez
NYU Grossman School of Medicine
Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-2576-1549
MD, Clinical Instructor
United States, New York, USAReferences
- Beckmann D, Lowman KL, Nargiso J, et al. Substance-induced Psychosis in Youth. Child and Adolescent Psychiatric Clinics of North America. 2020; 29(1):131-43. doi: 10.1016/j.chc.2019.08.006
- Fiorentini A, Volonteri LS, Dragogna F, et al. Substance-induced psychoses: a critical review of the literature. Current Drug Abuse Reviews. 2011;4(4): 228-40. doi: 10.2174/1874473711104040228
- Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of Psychotic Symptoms in Substance Users: A Comparison across Substances. Comprehensive Psychiatry. 2009;50(3):245-50. doi: 10.1016/j.comp psych.2008.07.009
- Biedermann F, Fleischhacker WW. Psychotic disorders in DSM-5 and ICD-11. CNS Spectrums. 2016; 21(4):349-54. doi: 10.1017/S1092852916000316
- Kraan T, Velthorst E, Koenders L, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and metaanalysis. Psychological Medicine. 2016;46(4):673-81. doi: 10.1017/S00332 91715002329
- Fedotov IA, Quattrone D, Shustov DI. Substance-induced psychosis and schizophrenia: the interaction point. I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):593-604. (In Russ). doi:10.23888/ PAVLOVJ2020284593-604
- Ham S, Kim TK, Chung S, et al. Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis. Experimental Neurobiology. 2017;26(1):11-24. doi: 10.5607/en.2017.26.1.11
- Dragogna F, Mauri MC, Marotta G, et al. Brain Metabolism in Substance-Induced Psychosis and Schizophrenia: A Preliminary PET Study. Neuropsychobiology. 2014;70(4):195-202. doi:10.1159/ 000366485
- Fischer M. Psychoses in the offspring of schizophrenic monozygotic twins and their normal cotwins. The British Journal of Psychiatry. 1971;118 (542):43-52. doi: 10.1192/bjp.118.542.43
- Ziedonis DM, Fisher W. Assessment and Treatment of Comorbid Substance Abuse in Individuals with Schizophrenia. Psychiatric Annals. 1994;24(9):477-83. doi: 10.3928/0048-5713-19940901-10
- Jatchavala C, Vittayanont A. Post-Traumatic Stress Disorder Symptoms among Patients with Substance-Related Disorders in the Restive A. Songklanagarind Medical Journal. 2017;35(2):121-32. doi: 10.31584/smj.2017.35.2.694
- Fowles DC. Schizophrenia: diathesis-stress revisited. Annual Review of Psychology. 1992;43:303-36. doi: 10.1146/annurev.ps.43.020192.001511
- Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bulletin. 1990;16(1):31-56. doi: 10.1093/schbul/16.1.31
- Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Review Psychiatry. 1999; 6(6):287-96. doi: 10.3109/10673229909017206
- Mueser KT, Drake RE, Wallach MA. Dual diagnosis: A review of etiological theories. Addictive Behaviors. 1998;23(6):717-34.
- Khokhar JY, Dwiel LL, Henricks AM, et al. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophrenia Research. 2018;194:78-85. doi: 10.1016/j.schres.2017.04.016
- Guloksuz S, van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Medicine. 2018; 48(2):229-44. doi: 10.1017/S0033291717001775
- Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. American Journal of Psychiatry. 2019;176(9):711-9. doi: 10.1176/appi. ajp.2019.18101217
- Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. American Journal of Psychiatry. 2018;175(4):343-50. doi: 10.1176/appi.ajp.2017.17020223
- Deng X, Huang Z, Li X, et al. Long-term follow-up of patients treated for psychotic symptoms that persist after stopping illicit drug use. Shanghai Archives of Psychiatry. 2012;24(5):271-8. doi: 10.3969/j.issn. 1002-0829.2012.05.004
- Solanki RK, Singh P, Midha A, et al. Schizophrenia: Impact on quality of life. Indian Journal of Psychiatry. 2008;50(3):181-6. doi: 10.4103/0019-5545.43632
- Auquier P, Lançon C, Rouillon F, et al. Mortality in schizophrenia. Pharmacoepidemiology and Drug Safety. 2006;15(12):873-9. doi: 10.1002/pds.1325
- McEvoy JP. The importance of early treatment of schizophrenia. Behavioral Healthcare. 2007;27(4):40-3